1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Opioid-induced Constipation Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Solid 1.2.3 Liquid 1.3 Market by Application 1.3.1 Global Opioid-induced Constipation Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Drugstore 1.3.3 Hospital 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Opioid-induced Constipation Market Perspective (2016-2027) 2.2 Opioid-induced Constipation Growth Trends by Regions 2.2.1 Opioid-induced Constipation Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Opioid-induced Constipation Historic Market Share by Regions (2016-2021) 2.2.3 Opioid-induced Constipation Forecasted Market Size by Regions (2022-2027) 2.3 Opioid-induced Constipation Industry Dynamic 2.3.1 Opioid-induced Constipation Market Trends 2.3.2 Opioid-induced Constipation Market Drivers 2.3.3 Opioid-induced Constipation Market Challenges 2.3.4 Opioid-induced Constipation Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Opioid-induced Constipation Players by Revenue 3.1.1 Global Top Opioid-induced Constipation Players by Revenue (2016-2021) 3.1.2 Global Opioid-induced Constipation Revenue Market Share by Players (2016-2021) 3.2 Global Opioid-induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Opioid-induced Constipation Revenue 3.4 Global Opioid-induced Constipation Market Concentration Ratio 3.4.1 Global Opioid-induced Constipation Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Opioid-induced Constipation Revenue in 2020 3.5 Opioid-induced Constipation Key Players Head office and Area Served 3.6 Key Players Opioid-induced Constipation Product Solution and Service 3.7 Date of Enter into Opioid-induced Constipation Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Opioid-induced Constipation Breakdown Data by Type 4.1 Global Opioid-induced Constipation Historic Market Size by Type (2016-2021) 4.2 Global Opioid-induced Constipation Forecasted Market Size by Type (2022-2027) 5 Opioid-induced Constipation Breakdown Data by Application 5.1 Global Opioid-induced Constipation Historic Market Size by Application (2016-2021) 5.2 Global Opioid-induced Constipation Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Opioid-induced Constipation Market Size (2016-2027) 6.2 North America Opioid-induced Constipation Market Size by Type 6.2.1 North America Opioid-induced Constipation Market Size by Type (2016-2021) 6.2.2 North America Opioid-induced Constipation Market Size by Type (2022-2027) 6.2.3 North America Opioid-induced Constipation Market Size by Type (2016-2027) 6.3 North America Opioid-induced Constipation Market Size by Application 6.3.1 North America Opioid-induced Constipation Market Size by Application (2016-2021) 6.3.2 North America Opioid-induced Constipation Market Size by Application (2022-2027) 6.3.3 North America Opioid-induced Constipation Market Size by Application (2016-2027) 6.4 North America Opioid-induced Constipation Market Size by Country 6.4.1 North America Opioid-induced Constipation Market Size by Country (2016-2021) 6.4.2 North America Opioid-induced Constipation Market Size by Country (2022-2027) 6.4.3 United States 6.4.3 Canada 7 Europe 7.1 Europe Opioid-induced Constipation Market Size (2016-2027) 7.2 Europe Opioid-induced Constipation Market Size by Type 7.2.1 Europe Opioid-induced Constipation Market Size by Type (2016-2021) 7.2.2 Europe Opioid-induced Constipation Market Size by Type (2022-2027) 7.2.3 Europe Opioid-induced Constipation Market Size by Type (2016-2027) 7.3 Europe Opioid-induced Constipation Market Size by Application 7.3.1 Europe Opioid-induced Constipation Market Size by Application (2016-2021) 7.3.2 Europe Opioid-induced Constipation Market Size by Application (2022-2027) 7.3.3 Europe Opioid-induced Constipation Market Size by Application (2016-2027) 7.4 Europe Opioid-induced Constipation Market Size by Country 7.4.1 Europe Opioid-induced Constipation Market Size by Country (2016-2021) 7.4.2 Europe Opioid-induced Constipation Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Opioid-induced Constipation Market Size (2016-2027) 8.2 Asia-Pacific Opioid-induced Constipation Market Size by Type 8.2.1 Asia-Pacific Opioid-induced Constipation Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Opioid-induced Constipation Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Opioid-induced Constipation Market Size by Type (2016-2027) 8.3 Asia-Pacific Opioid-induced Constipation Market Size by Application 8.3.1 Asia-Pacific Opioid-induced Constipation Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Opioid-induced Constipation Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Opioid-induced Constipation Market Size by Application (2016-2027) 8.4 Asia-Pacific Opioid-induced Constipation Market Size by Region 8.4.1 Asia-Pacific Opioid-induced Constipation Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Opioid-induced Constipation Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Opioid-induced Constipation Market Size (2016-2027) 9.2 Latin America Opioid-induced Constipation Market Size by Type 9.2.1 Latin America Opioid-induced Constipation Market Size by Type (2016-2021) 9.2.2 Latin America Opioid-induced Constipation Market Size by Type (2022-2027) 9.2.3 Latin America Opioid-induced Constipation Market Size by Type (2016-2027) 9.3 Latin America Opioid-induced Constipation Market Size by Application 9.3.1 Latin America Opioid-induced Constipation Market Size by Application (2016-2021) 9.3.2 Latin America Opioid-induced Constipation Market Size by Application (2022-2027) 9.3.3 Latin America Opioid-induced Constipation Market Size by Application (2016-2027) 9.4 Latin America Opioid-induced Constipation Market Size by Country 9.4.1 Latin America Opioid-induced Constipation Market Size by Country (2016-2021) 9.4.2 Latin America Opioid-induced Constipation Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Opioid-induced Constipation Market Size (2016-2027) 10.2 Middle East & Africa Opioid-induced Constipation Market Size by Type 10.2.1 Middle East & Africa Opioid-induced Constipation Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Opioid-induced Constipation Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Opioid-induced Constipation Market Size by Type (2016-2027) 10.3 Middle East & Africa Opioid-induced Constipation Market Size by Application 10.3.1 Middle East & Africa Opioid-induced Constipation Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Opioid-induced Constipation Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Opioid-induced Constipation Market Size by Application (2016-2027) 10.4 Middle East & Africa Opioid-induced Constipation Market Size by Country 10.4.1 Middle East & Africa Opioid-induced Constipation Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Opioid-induced Constipation Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 AstraZeneca 11.1.1 AstraZeneca Company Details 11.1.2 AstraZeneca Business Overview 11.1.3 AstraZeneca Opioid-induced Constipation Introduction 11.1.4 AstraZeneca Revenue in Opioid-induced Constipation Business (2016-2021) 11.1.5 AstraZeneca Recent Development 11.2 Takeda Pharmaceutical 11.2.1 Takeda Pharmaceutical Company Details 11.2.2 Takeda Pharmaceutical Business Overview 11.2.3 Takeda Pharmaceutical Opioid-induced Constipation Introduction 11.2.4 Takeda Pharmaceutical Revenue in Opioid-induced Constipation Business (2016-2021) 11.2.5 Takeda Pharmaceutical Recent Development 11.3 Bausch Health 11.3.1 Bausch Health Company Details 11.3.2 Bausch Health Business Overview 11.3.3 Bausch Health Opioid-induced Constipation Introduction 11.3.4 Bausch Health Revenue in Opioid-induced Constipation Business (2016-2021) 11.3.5 Bausch Health Recent Development 11.4 Abbott 11.4.1 Abbott Company Details 11.4.2 Abbott Business Overview 11.4.3 Abbott Opioid-induced Constipation Introduction 11.4.4 Abbott Revenue in Opioid-induced Constipation Business (2016-2021) 11.4.5 Abbott Recent Development 11.5 Bayer 11.5.1 Bayer Company Details 11.5.2 Bayer Business Overview 11.5.3 Bayer Opioid-induced Constipation Introduction 11.5.4 Bayer Revenue in Opioid-induced Constipation Business (2016-2021) 11.5.5 Bayer Recent Development 11.6 Boehringer Ingelheim 11.6.1 Boehringer Ingelheim Company Details 11.6.2 Boehringer Ingelheim Business Overview 11.6.3 Boehringer Ingelheim Opioid-induced Constipation Introduction 11.6.4 Boehringer Ingelheim Revenue in Opioid-induced Constipation Business (2016-2021) 11.6.5 Boehringer Ingelheim Recent Development 11.7 C.B. Fleet 11.7.1 C.B. Fleet Company Details 11.7.2 C.B. Fleet Business Overview 11.7.3 C.B. Fleet Opioid-induced Constipation Introduction 11.7.4 C.B. Fleet Revenue in Opioid-induced Constipation Business (2016-2021) 11.7.5 C.B. Fleet Recent Development 11.8 Cosmo Pharmaceuticals 11.8.1 Cosmo Pharmaceuticals Company Details 11.8.2 Cosmo Pharmaceuticals Business Overview 11.8.3 Cosmo Pharmaceuticals Opioid-induced Constipation Introduction 11.8.4 Cosmo Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) 11.8.5 Cosmo Pharmaceuticals Recent Development 11.9 Daewoong 11.9.1 Daewoong Company Details 11.9.2 Daewoong Business Overview 11.9.3 Daewoong Opioid-induced Constipation Introduction 11.9.4 Daewoong Revenue in Opioid-induced Constipation Business (2016-2021) 11.9.5 Daewoong Recent Development 11.10 Daiichi Sankyo 11.10.1 Daiichi Sankyo Company Details 11.10.2 Daiichi Sankyo Business Overview 11.10.3 Daiichi Sankyo Opioid-induced Constipation Introduction 11.10.4 Daiichi Sankyo Revenue in Opioid-induced Constipation Business (2016-2021) 11.10.5 Daiichi Sankyo Recent Development 11.11 GlaxoSmithKline 11.11.1 GlaxoSmithKline Company Details 11.11.2 GlaxoSmithKline Business Overview 11.11.3 GlaxoSmithKline Opioid-induced Constipation Introduction 11.11.4 GlaxoSmithKline Revenue in Opioid-induced Constipation Business (2016-2021) 11.11.5 GlaxoSmithKline Recent Development 11.12 Ironwood Pharmaceuticals 11.12.1 Ironwood Pharmaceuticals Company Details 11.12.2 Ironwood Pharmaceuticals Business Overview 11.12.3 Ironwood Pharmaceuticals Opioid-induced Constipation Introduction 11.12.4 Ironwood Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) 11.12.5 Ironwood Pharmaceuticals Recent Development 11.13 Johnson and Johnson 11.13.1 Johnson and Johnson Company Details 11.13.2 Johnson and Johnson Business Overview 11.13.3 Johnson and Johnson Opioid-induced Constipation Introduction 11.13.4 Johnson and Johnson Revenue in Opioid-induced Constipation Business (2016-2021) 11.13.5 Johnson and Johnson Recent Development 11.14 Merck 11.14.1 Merck Company Details 11.14.2 Merck Business Overview 11.14.3 Merck Opioid-induced Constipation Introduction 11.14.4 Merck Revenue in Opioid-induced Constipation Business (2016-2021) 11.14.5 Merck Recent Development 11.15 Mundipharma 11.15.1 Mundipharma Company Details 11.15.2 Mundipharma Business Overview 11.15.3 Mundipharma Opioid-induced Constipation Introduction 11.15.4 Mundipharma Revenue in Opioid-induced Constipation Business (2016-2021) 11.15.5 Mundipharma Recent Development 11.16 Nektar Therapeutics 11.16.1 Nektar Therapeutics Company Details 11.16.2 Nektar Therapeutics Business Overview 11.16.3 Nektar Therapeutics Opioid-induced Constipation Introduction 11.16.4 Nektar Therapeutics Revenue in Opioid-induced Constipation Business (2016-2021) 11.16.5 Nektar Therapeutics Recent Development 11.17 Pfizer 11.17.1 Pfizer Company Details 11.17.2 Pfizer Business Overview 11.17.3 Pfizer Opioid-induced Constipation Introduction 11.17.4 Pfizer Revenue in Opioid-induced Constipation Business (2016-2021) 11.17.5 Pfizer Recent Development 11.18 Progenics Pharmaceuticals 11.18.1 Progenics Pharmaceuticals Company Details 11.18.2 Progenics Pharmaceuticals Business Overview 11.18.3 Progenics Pharmaceuticals Opioid-induced Constipation Introduction 11.18.4 Progenics Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) 11.18.5 Progenics Pharmaceuticals Recent Development 11.18 Shionogi .1 Shionogi Company Details .2 Shionogi Business Overview .3 Shionogi Opioid-induced Constipation Introduction .4 Shionogi Revenue in Opioid-induced Constipation Business (2016-2021) .5 Shionogi Recent Development 11.20 SLA Pharma 11.20.1 SLA Pharma Company Details 11.20.2 SLA Pharma Business Overview 11.20.3 SLA Pharma Opioid-induced Constipation Introduction 11.20.4 SLA Pharma Revenue in Opioid-induced Constipation Business (2016-2021) 11.20.5 SLA Pharma Recent Development 11.21 Sucampo 11.21.1 Sucampo Company Details 11.21.2 Sucampo Business Overview 11.21.3 Sucampo Opioid-induced Constipation Introduction 11.21.4 Sucampo Revenue in Opioid-induced Constipation Business (2016-2021) 11.21.5 Sucampo Recent Development 11.22 Synergy Pharmaceuticals 11.22.1 Synergy Pharmaceuticals Company Details 11.22.2 Synergy Pharmaceuticals Business Overview 11.22.3 Synergy Pharmaceuticals Opioid-induced Constipation Introduction 11.22.4 Synergy Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) 11.22.5 Synergy Pharmaceuticals Recent Development 11.23 Theravance 11.23.1 Theravance Company Details 11.23.2 Theravance Business Overview 11.23.3 Theravance Opioid-induced Constipation Introduction 11.23.4 Theravance Revenue in Opioid-induced Constipation Business (2016-2021) 11.23.5 Theravance Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Opioid-induced Constipation Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Solid Table 3. Key Players of Liquid Table 4. Global Opioid-induced Constipation Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 5. Global Opioid-induced Constipation Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Opioid-induced Constipation Market Size by Regions (2016-2021) & (US$ Million) Table 7. Global Opioid-induced Constipation Market Share by Regions (2016-2021) Table 8. Global Opioid-induced Constipation Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 9. Global Opioid-induced Constipation Market Share by Regions (2022-2027) Table 10. Opioid-induced Constipation Market Trends Table 11. Opioid-induced Constipation Market Drivers Table 12. Opioid-induced Constipation Market Challenges Table 13. Opioid-induced Constipation Market Restraints Table 14. Global Opioid-induced Constipation Revenue by Players (2016-2021) & (US$ Million) Table 15. Global Opioid-induced Constipation Market Share by Players (2016-2021) Table 16. Global Top Opioid-induced Constipation Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-induced Constipation as of 2020) Table 17. Ranking of Global Top Opioid-induced Constipation Companies by Revenue (US$ Million) in 2020 Table 18. Global 5 Largest Players Market Share by Opioid-induced Constipation Revenue (CR5 and HHI) & (2016-2021) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Opioid-induced Constipation Product Solution and Service Table 21. Date of Enter into Opioid-induced Constipation Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million) Table 24. Global Opioid-induced Constipation Revenue Market Share by Type (2016-2021) Table 25. Global Opioid-induced Constipation Forecasted Market Size by Type (2022-2027) (US$ Million) Table 26. Global Opioid-induced Constipation Revenue Market Share by Type (2022-2027) & (US$ Million) Table 27. Global Opioid-induced Constipation Market Size Share by Application (2016-2021) & (US$ Million) Table 28. Global Opioid-induced Constipation Revenue Market Share by Application (2016-2021) Table 29. Global Opioid-induced Constipation Forecasted Market Size by Application (2022-2027) (US$ Million) Table 30. Global Opioid-induced Constipation Revenue Market Share by Application (2022-2027) & (US$ Million) Table 31. North America Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million) Table 32. North America Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million) Table 33. North America Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million) Table 34. North America Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million) Table 35. North America Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million) Table 36. North America Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million) Table 37. Europe Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million) Table 38. Europe Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million) Table 39. Europe Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million) Table 40. Europe Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million) Table 41. Europe Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million) Table 42. Europe Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million) Table 43. Asia-Pacific Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million) Table 44. Asia-Pacific Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million) Table 45. Asia-Pacific Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million) Table 46. Asia-Pacific Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million) Table 47. Asia-Pacific Opioid-induced Constipation Market Size by Region (2016-2021) & (US$ Million) Table 48. Asia-Pacific Opioid-induced Constipation Market Size by Region (2022-2027) & (US$ Million) Table 49. Latin America Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million) Table 50. Latin America Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million) Table 51. Latin America Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million) Table 52. Latin America Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million) Table 53. Latin America Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million) Table 54. Latin America Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million) Table 55. Middle East & Africa Opioid-induced Constipation Market Size by Type (2016-2021) (US$ Million) Table 56. Middle East & Africa Opioid-induced Constipation Market Size by Type (2022-2027) & (US$ Million) Table 57. Middle East & Africa Opioid-induced Constipation Market Size by Application (2016-2021) (US$ Million) Table 58. Middle East & Africa Opioid-induced Constipation Market Size by Application (2022-2027) & (US$ Million) Table 59. Middle East & Africa Opioid-induced Constipation Market Size by Country (2016-2021) & (US$ Million) Table 60. Middle East & Africa Opioid-induced Constipation Market Size by Country (2022-2027) & (US$ Million) Table 61. AstraZeneca Company Details Table 62. AstraZeneca Business Overview Table 63. AstraZeneca Opioid-induced Constipation Product Table 64. AstraZeneca Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 65. AstraZeneca Recent Development Table 66. Takeda Pharmaceutical Company Details Table 67. Takeda Pharmaceutical Business Overview Table 68. Takeda Pharmaceutical Opioid-induced Constipation Product Table 69. Takeda Pharmaceutical Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 70. Takeda Pharmaceutical Recent Development Table 71. Bausch Health Company Details Table 72. Bausch Health Business Overview Table 73. Bausch Health Opioid-induced Constipation Product Table 74. Bausch Health Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 75. Bausch Health Recent Development Table 76. Abbott Company Details Table 77. Abbott Business Overview Table 78. Abbott Opioid-induced Constipation Product Table 79. Abbott Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 80. Abbott Recent Development Table 81. Bayer Company Details Table 82. Bayer Business Overview Table 83. Bayer Opioid-induced Constipation Product Table 84. Bayer Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 85. Bayer Recent Development Table 86. Boehringer Ingelheim Company Details Table 87. Boehringer Ingelheim Business Overview Table 88. Boehringer Ingelheim Opioid-induced Constipation Product Table 89. Boehringer Ingelheim Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 90. Boehringer Ingelheim Recent Development Table 91. C.B. Fleet Company Details Table 92. C.B. Fleet Business Overview Table 93. C.B. Fleet Opioid-induced Constipation Product Table 94. C.B. Fleet Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 95. C.B. Fleet Recent Development Table 96. Cosmo Pharmaceuticals Company Details Table 97. Cosmo Pharmaceuticals Business Overview Table 98. Cosmo Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 99. Cosmo Pharmaceuticals Recent Development Table 100. Daewoong Company Details Table 101. Daewoong Business Overview Table 102. Daewoong Opioid-induced Constipation Product Table 103. Daewoong Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 104. Daewoong Recent Development Table 105. Daiichi Sankyo Company Details Table 106. Daiichi Sankyo Business Overview Table 107. Daiichi Sankyo Opioid-induced Constipation Product Table 108. Daiichi Sankyo Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 109. Daiichi Sankyo Recent Development Table 110. GlaxoSmithKline Company Details Table 111. GlaxoSmithKline Business Overview Table 112. GlaxoSmithKline Opioid-induced Constipation Product Table 113. GlaxoSmithKline Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 114. GlaxoSmithKline Recent Development Table 115. Ironwood Pharmaceuticals Company Details Table 116. Ironwood Pharmaceuticals Business Overview Table 117. Ironwood Pharmaceuticals Opioid-induced Constipation Product Table 118. Ironwood Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 119. Ironwood Pharmaceuticals Recent Development Table 120. Johnson and Johnson Company Details Table 121. Johnson and Johnson Business Overview Table 122. Johnson and Johnson Opioid-induced Constipation Product Table 123. Johnson and Johnson Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 124. Johnson and Johnson Recent Development Table 125. Merck Company Details Table 126. Merck Business Overview Table 127. Merck Opioid-induced Constipation Product Table 128. Merck Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 129. Merck Recent Development Table 130. Mundipharma Company Details Table 131. Mundipharma Business Overview Table 132. Mundipharma Opioid-induced Constipation Product Table 133. Mundipharma Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 134. Mundipharma Recent Development Table 135. Nektar Therapeutics Company Details Table 136. Nektar Therapeutics Business Overview Table 137. Nektar Therapeutics Opioid-induced Constipation Product Table 138. Nektar Therapeutics Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 139. Nektar Therapeutics Recent Development Table 140. Pfizer Company Details Table 141. Pfizer Business Overview Table 142. Pfizer Opioid-induced Constipation Product Table 143. Pfizer Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 144. Pfizer Recent Development Table 145. Progenics Pharmaceuticals Company Details Table 146. Progenics Pharmaceuticals Business Overview Table 147. Progenics Pharmaceuticals Opioid-induced Constipation Product Table 148. Progenics Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 149. Progenics Pharmaceuticals Recent Development Table 150. Shionogi Company Details Table 151. Shionogi Business Overview Table 152. Shionogi Opioid-induced Constipation Product Table 153. Shionogi Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 154. Shionogi Recent Development Table 155. SLA Pharma Company Details Table 156. SLA Pharma Business Overview Table 157. SLA Pharma Opioid-induced Constipation Product Table 158. SLA Pharma Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 159. SLA Pharma Recent Development Table 160. Sucampo Company Details Table 161. Sucampo Business Overview Table 162. Sucampo Opioid-induced Constipation Product Table 163. Sucampo Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 164. Sucampo Recent Development Table 165. Synergy Pharmaceuticals Company Details Table 166. Synergy Pharmaceuticals Business Overview Table 167. Synergy Pharmaceuticals Opioid-induced Constipation Product Table 168. Synergy Pharmaceuticals Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 169. Synergy Pharmaceuticals Recent Development Table 170. Theravance Company Details Table 171. Theravance Business Overview Table 172. Theravance Opioid-induced Constipation Product Table 173. Theravance Revenue in Opioid-induced Constipation Business (2016-2021) & (US$ Million) Table 174. Theravance Recent Development Table 175. Research Programs/Design for This Report Table 176. Key Data Information from Secondary Sources Table 177. Key Data Information from Primary Sources List of Figures Figure 1. Global Opioid-induced Constipation Market Share by Type: 2020 VS 2027 Figure 2. Solid Features Figure 3. Liquid Features Figure 4. Global Opioid-induced Constipation Market Share by Application: 2020 VS 2027 Figure 5. Drugstore Case Studies Figure 6. Hospital Case Studies Figure 7. Others Case Studies Figure 8. Opioid-induced Constipation Report Years Considered Figure 9. Global Opioid-induced Constipation Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 10. Global Opioid-induced Constipation Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 11. Global Opioid-induced Constipation Market Share by Regions: 2020 VS 2027 Figure 12. Global Opioid-induced Constipation Market Share by Regions (2022-2027) Figure 13. Global Opioid-induced Constipation Market Share by Players in 2020 Figure 14. Global Top Opioid-induced Constipation Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-induced Constipation as of 2020 Figure 15. The Top 10 and 5 Players Market Share by Opioid-induced Constipation Revenue in 2020 Figure 16. Global Opioid-induced Constipation Revenue Market Share by Type (2016-2021) Figure 17. Global Opioid-induced Constipation Revenue Market Share by Type (2022-2027) Figure 18. North America Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 19. North America Opioid-induced Constipation Market Share by Type (2016-2027) Figure 20. North America Opioid-induced Constipation Market Share by Application (2016-2027) Figure 21. North America Opioid-induced Constipation Market Share by Country (2016-2027) Figure 22. United States Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 23. Canada Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Europe Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe Opioid-induced Constipation Market Share by Type (2016-2027) Figure 26. Europe Opioid-induced Constipation Market Share by Application (2016-2027) Figure 27. Europe Opioid-induced Constipation Market Share by Country (2016-2027) Figure 28. Germany Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. France Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. U.K. Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Italy Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Russia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Nordic Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Asia-Pacific Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific Opioid-induced Constipation Market Share by Type (2016-2027) Figure 36. Asia-Pacific Opioid-induced Constipation Market Share by Application (2016-2027) Figure 37. Asia-Pacific Opioid-induced Constipation Market Share by Region (2016-2027) Figure 38. China Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Japan Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. South Korea Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Southeast Asia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. India Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Australia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Latin America Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America Opioid-induced Constipation Market Share by Type (2016-2027) Figure 46. Latin America Opioid-induced Constipation Market Share by Application (2016-2027) Figure 47. Latin America Opioid-induced Constipation Market Share by Country (2016-2027) Figure 48. Mexico Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Brazil Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Middle East & Africa Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa Opioid-induced Constipation Market Share by Type (2016-2027) Figure 52. Middle East & Africa Opioid-induced Constipation Market Share by Application (2016-2027) Figure 53. Middle East & Africa Opioid-induced Constipation Market Share by Country (2016-2027) Figure 54. Turkey Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Saudi Arabia Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. UAE Opioid-induced Constipation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. AstraZeneca Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 58. Takeda Pharmaceutical Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 59. Bausch Health Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 60. Abbott Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 61. Bayer Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 62. Boehringer Ingelheim Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 63. C.B. Fleet Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 64. Cosmo Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 65. Daewoong Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 66. Daiichi Sankyo Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 67. GlaxoSmithKline Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 68. Ironwood Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 69. Johnson and Johnson Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 70. Merck Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 71. Mundipharma Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 72. Nektar Therapeutics Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 73. Pfizer Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 74. Progenics Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 75. Shionogi Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 76. SLA Pharma Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 77. Sucampo Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 78. Synergy Pharmaceuticals Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 79. Theravance Revenue Growth Rate in Opioid-induced Constipation Business (2016-2021) Figure 80. Bottom-up and Top-down Approaches for This Report Figure 81. Data Triangulation Figure 82. Key Executives Interviewed

AstraZeneca Takeda Pharmaceutical Bausch Health Abbott Bayer Boehringer Ingelheim C.B. Fleet Cosmo Pharmaceuticals Daewoong Daiichi Sankyo GlaxoSmithKline Ironwood Pharmaceuticals Johnson and Johnson Merck Mundipharma Nektar Therapeutics Pfizer Progenics Pharmaceuticals Shionogi SLA Pharma Sucampo Synergy Pharmaceuticals Theravance